Gentlemen & Women, as I always say, invest wisely, smartly and do your
DD before buying. I like finding undervalued companies. I have done my
research/DD and I really couldnt pass this one up, 'GLOB', CHARTS/
TECHNICALS/VOLUME indicate and show that this will be rallying from
HERE ON OUT. They have a GREAT WEBSITE, GREAT PROFITABILITY, CANT
DOUBT THIS COMPANY's POTENTIAL.
Ok what got me hooked and see this as long term, was two simple HUGE
statements made: "New RFID Product is Estimated to be a $1 Billion
'Green Field' Market Opportunity Internationally and is Expected to
Generate Significant Revenues and Profits" & "The product is currently
not for sale in the U.S., but is being sold in Europe. Global Med
intends to apply for FDA clearance of the product in the near future."
THOSE two sentences has made me a believer and i'm in it especially
when they apply for FDA clearance.
QUICK LOOK: With a possible Billion $ product and also breaking into
US in the future, a small 36MIL Outstanding amount of shares, watch
the 52 week high of $1.39 be shattered! I repeat shattered!
*Financial Strong*:
STRONG BALANCE SHEET+CASH FLOW+PROFITABILITY-HUGE FUTURE GROWTH
POTENTIAL, here are some highlights of their 1st half ending June
30th, 2009:
-First Half Revenues are Record High-First Half and Q2 Revenues Rose
74% and 66%, Respectively-Recurring Revenues Climb 20%
-Global Med's record revenues of $16.418 million for the first half of
2009 represent an increase of $6.980 million or 74% over the $9.438
million recorded for the first half of 2008. In the first half of
2009, operating income improved to $1.678 million from $958 thousand
during the first half of last year. The Company's net income for the
first half of 2009 was $593 thousand, or $0.02 per basic common share
outstanding, versus $512 thousand, or $0.02 per basic common share
outstanding, for the first half of 2008.
-Global Med's revenues of $8.059 million for the second quarter of
2009 represent an increase of $3.214 million or 66% over the $4.845
million recorded for the comparable 2008 period. In the second quarter
of 2009, operating income improved to $621 thousand from $333 thousand
during the comparable 2008 period. The Company's net income for the
second quarter of 2009 increased 79% to $272 thousand, or $0.01 per
basic common share outstanding, from $152 thousand, or $0.01 per basic
common share outstanding, for the comparable 2008 period.
-Global Med's cash flow from operations for the first half of 2009 was
$3.891 million, a more than four-fold increase over the $887 thousand
recorded for the first half of 2008.
Recurring annual maintenance revenues for the quarter were running at
an annualized rate of over $16.7 million. Based on the backlog as of
June 30, 2009, the Company's annual recurring revenues, when all
contracted customer sites are implemented, will be nearly $18.0
million, an increase of 20% over 2008. The Company's backlog of
unrecognized software license fees and implementation fees as of June
30, 2009 was approximately $8.8 million, an increase of 59% over
2008.
With this said, LET THE RALLY BEGIN....
My DD on recent news and they report a steady stream every week:
***9-17-09***
Global Med Technologies, Inc.'s CEO to Make Major New Product
Announcement the Morning of the LDV Investor Conference and Will Demo
the Product on Wednesday, September 23, 2009 Global Med Technologies
((R)), Inc. ("Global Med" or the "Company") (OTC Bulletin Board:
GLOB), an international healthcare information technology company,
today announced that Michael I. Ruxin, M.D., Global Med's Chairman and
CEO, will make a major new product announcement the morning of the LDV
Growth & Value Equity Conference which will be held at The Embassy
Suites Boca Raton Hotel, Boca Raton, Florida. Dr. Ruxin will also demo
the breakthrough product at the conference. "====The breakthrough
medical product announcement will be concerning an innovative,
European RFID medical device, that has just come on the market, and
that has little competition with older medical device technologies
that currently exist in the same area. Market penetration of these
older medical devices is less than 10% in the U.S. market and has
minimal penetration in international markets. The main reasons for the
small market penetration globally are the high cost of these older
medical devices, lengthy staff education needed to implement, and
overall difficulty of use. Global Med's new RFID product will overcome
all three of these concerns. The product is currently not for sale in
the U.S., but is being sold in Europe. Global Med intends to apply for
FDA clearance of the product in the near future.===="
*9-15-09*
Global Med Technologies((R)), Inc. ("Global Med" or the "Company")
(OTC Bulletin Board: GLOB), an international e-Health, medical
information technology company, today announced that its Inlog
subsidiary has licensed its EdgeCell Cellular Therapy Software and
EdgeLab/HLA Laboratory Information Management Software for Human
Leukocyte Antigen matching (marketed as "Labo Serveur" in France) to
the Hema-Quebec in Quebec, Canada Hema-Quebec will use EdgeCell in its
Stem Cell Laboratory and Public Cord Blood Bank. EdgeCell is a state-
of-the-art Cellular Therapy software solution for hospitals, surgery
centers and health care facilities. EdgeCell fully tracks the
procurement process including the medical history questionnaire, all
required testing including specimen reception and infectious disease
testing, product preparation, packaging, labeling and storage, as well
as crossmatching and distribution. EdgeCell incorporates an extensive
list of safety features along with full traceability
and generation of regulatory documentation.
*9-10-09*
Global Med Technologies((R)), Inc. ("Global Med" or the "Company")
(OTC Bulletin Board: GLOB), an international e-Health, medical
information technology company, today announced that its Wyndgate
Technologies division has licensed and deployed its SafeTrace Tx((R))
transfusion management software to Schuylkill Health of Pottsville,
Pennsylvania. Schuylkill is also using the services of Global Med's
PeopleMed((R)) subsidiary to validate the systems before go-live.
Terms of the agreement were not disclosed.
About Global Med Technologies((R)), Inc.
Global Med Technologies, Inc. is an international healthcare
information technology company which develops regulated and non-
regulated products and services for the healthcare industry. As a
leading provider of blood and laboratory systems and services, Global
Med's products are deployed in 20 countries and serve over 2,100
transfusion centers, blood banks and laboratory sites. Global Med's
domestic companies are Wyndgate Technologies((R)), a leader in
software products and services for donor centers and hospital
transfusion services; eDonor((R)), which offers web-based donor
relationship management systems; and PeopleMed((TM)), Inc., which
implements cost-effective software validation, consulting and
compliance solutions to hospitals and donor centers. Global Med's
European subsidiary, Inlog, SA, is a leading developer of *donor
center and *transfusion management systems as well as cellular therapy
software, *laboratory information systems and quality assurance
medical software systems internationally.
For more information about Global Med's products and services, please
call 800-996-3428 or visit globalmedtech.com
COME DOUBT THIS NOW on the DD!!
